Genetic Study of Seizure Patients Who Respond To Charlotte’s Web Strain Underway

Share this with your friends

Researchers in Colorado are focusing on cannabis’ ability to alleviate seizures. Specifically, medical researchers at the University of Colorado Anshutz Medical Campus will be doing a study about the efficacy of the strain commonly known as Charlotte’s Web and its ability to help slow, decrease, or stop seizure activity in children with Dravet syndrome.

The study will look at patients with Dravet syndrome who have responded to treatment with a high-CBD oil derived from the Charlotte’s Web strain. Then, the genetic information of each patient will be collected and compared. Researchers are hoping to find a genetic component to responsiveness to cannabis treatment that explains why some people respond to cannabinoid treatments while others do not. This research may also help with screening for treatments in the future and may help explain the process by which cannabis suppresses seizure activity.

The mainstream media is very excited about this study but seems to have missed one of the more important implications of the study: it may well help establish the importance of whole plant medicine and a wide range of high-CBD strains being available to patients.

Currently, much of the medical world’s focus on high-cannabidiol strains is directly on the Charlotte’s Web strain, despite it being owned (and under lock and key genetically speaking) by the Realm of Caring’s Stanley Brothers. There are many other strains that have high CBD to THC ratios, but they are being ignored and passed over. Research indicating that THC is a necessary component or that different patients respond to strains differently (beliefs based on anecdotal information that are readily accepted by most within the medical cannabis community) will help refocus legalization efforts on whole plant medicine and THC-inclusive medical marijuana laws.

The study will be ongoing through the end of winter in 2016, but the results will likely be worth the wait. Whether researchers will find a genetic component to individual’s responsiveness to cannabis therapy or not, this study will help shed light on the one of the most compelling uses of cannabidiol for medical applications. Best of luck to the researchers and the patients participating in this study (and their parents or guardians as well).

For previous Ladybud coverage of high-CBD medical cannabis, click here.

Photo Credit: PublicDomainPictures under public domain via Pixabay